In a recent discussion, Jeremy Levin, a veteran in the biotech sector and founder of Ovid Therapeutics, expressed concerns about the future of the American biotech industry. While acknowledging the remarkable scientific breakthroughs being achieved, Levin cautioned that the foundational institutions supporting these advancements are under strain. He attributes this instability to factors such as political upheaval, diminishing public trust, and a shift towards short-term investment strategies. In his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust,” Levin argues that these issues pose significant risks to the industry's leadership in the U.S. He advocates for federal reforms that would encourage investment in biotech and urges pharmaceutical companies to vocalize the detrimental effects of regulatory challenges. Levin stresses the critical need for the industry to unite and advocate for itself amidst these turbulent times, as silence from industry leaders could exacerbate the challenges faced by the sector. His insights were shared during an episode of “The Readout Loud,” where he discussed the pressing need for action to secure the future of biotechnology in America.